UPDATE: Oppenheimer Holdings Reiterates Outperform Rating, Raises PT on Chemed Corporation

In a report published Wednesday, Oppenheimer Holdings reiterated its Outperform rating on Chemed Corporation

, and raised its price target from $75.00 to $80.00. Oppenheimer Holdings noted, “We attended meetings with Chemed management, and continue to believe CHE remains an attractive stock to own heading into '13. On the hospice side, the business remains well positioned, as reimbursement risks remain low, particularly as lawmakers look for ways to control healthcare costs. Meanwhile, Roto-Rooter continues to provide solid cash flow, which could be applied toward future acquisitions. As a result of the continued positive outlook and a shift to FY2013 estimates as a basis, we are raising our price target on CHE to $80 from $75.” Chemed Corporation closed on Tuesday at $70.15.